KRKA: Start of share buy-back programme

opublikowano: 2026-07-20 08:58

Spis treści:
1. REPORT
2. ESAP METADATE
3. INFORMATION ABOUT THE ENTITY
4. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. Share buy-back programme schedule from July to December 2026.pdf

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No

31

/

2026

Date of issue:

2026-07-20

Short name of the issuer

KRKA

Subject

Start of share buy-back programme

Official market - legal basis

Art. 17 ust. 1 Rozporządzenia MAR – informacje poufne

Unofficial market - legal basis

Contents of the report:

On 9 July 2026, the 32nd Annual General Meeting authorized the Management Board for the acquisition of treasury shares in accordance with the paragraph 1, indent 8 of Article 247 of the Companies Act (ZGD-1).

The company is disclosing that it will commence the acquisition of treasury shares in accordance with this authorization under the following conditions:

* The sole purpose of a share buy-back programme is share capital decrease of the issuer.

* The maximum pecuniary amount allocated to the programme is EUR 251,902,480.

* The maximum number of shares to be acquired is 762,763.

* Duration of the programme is 36 months from the date of the General Meeting authorization.

Shares will be acquired according to the enclosed six-month share buy-back programme schedule until the end of 2026, on the regulated market at the respective market price and on terms that will not affect prevailing market conditions. The company will announce the continuation of the share buy-back programme with a new six-month share buy-back schedule at least 30 days before the expiration of valid schedule.

The public will be regularly informed about these acquisitions of treasury shares.

The notice will be published on the Company's website (www.krka.biz) from 20 July 2026 onwards, for a period of at least 5 years.

Annexes

File

Description

Share buy-back programme schedule from July to December 2026.pdf

Share buy-back programme schedule from July to December 2026

Legal framework

Type of information

TRANSD

Acquisition or disposal of an issuer’s own shares

RegulatoryData

Collection Body

PLKNF

Unique data record identifier

Type of submission

New (to be used for new information)

Voluntary information flag

Date or period covered [Date or beginning of the period to which the information relates]

2026-07-20

Date or period covered [Date or end of the period to which the information relates]

2026-07-20

Personal data flag

Macierzyste państwo członkowskie, w stosownych przypadkach

PL

DocumentReference

Język, w którym przekazano informacje

Oryginał (ORIG) czy tłumaczenie (TRAN)

Numer referencyjny pliku danych

PL

ORIG

SubmittingEntity

Submitting entity LEI

or

Submitting entity name - natural person

RelatedEntity/LegalPerson

Entity LEI

Size of the entity

Industry sector(s)

549300H9RLRTRTLRUZ73

Large group

(acc. NACE): C

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification

of the WSE in Warsow)

8501

Nove Mesto

(post code)

(city)

Smarjeska

6

(street)

(number)

+386 7 331 21 11

+386 7 332 15 37

(phone number)

(fax)

(e-mail)

(web site)

nie dotyczy

(NIP)

(REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date

Name

Position / Function

Signature

2026-07-20

Jože Colarič

President of the Management Board and CEO